Engineered immune cells take on Hard-to-Treat prostate cancer

NCT ID NCT05805371

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial is testing a new treatment for men with a tough-to-treat form of prostate cancer that has spread and no longer responds to hormone therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells that have a specific marker called PSCA. Some participants will also receive radiation therapy. The main goals are to check safety, find the best dose, and see if the treatment can shrink tumors or lower PSA levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

PSCA-targeting CAR-T cells (a type of immune cell therapy made from the patient's own blood)

What this could lead to

If it works, this could point toward a new treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.

What could go wrong

This is a very early phase 1 trial with only 21 participants, so safety and dosing are still being figured out. CAR-T cell therapy can cause serious side effects like cytokine release syndrome and nerve problems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact